Research Associate- Welch Group: Global reprogramming of virulence and AMR in Pseudomonas aeruginosa bymutations in FusA1 (Fixed Term)

The University of Cambridge is one of the world's oldest universities and leading academic centres. If you're looking for a new challenge and would like excellent benefits, extensive learning opportunities and a stimulating working environment in return for your skills and contribution, there could be a job here for you.

Applications are invited for a Research Associate position in the laboratory of Professor Martin Welch in the Department of Biochemistry, University of Cambridge.

Mutations in fusA1 are now recognized as being responsible for high level resistance to aminoglycoside antibiotics. These mutations are particularly prevalent in the critical priority pathogen, Pseudomonas aeruginosa, which is ubiquitous in the built environment and is a major cause of potentially life threatening infections in immune-impaired individuals and among people who are genetically pre-disposed towards infection (eg, people with CF). However, we currently have little idea about why mutations in fusA1 lead to AMR. FusA1 encodes a probable ribosome recycling factor helping ribosomes to "drop off" the mRNA message when they encounter a "stall signal". Ribosomal pausing at most stall sites is usually easily overcome if the FusA1 is functioning normally. However, based on our preliminary experiments, we suspect that the ability of mutant forms of FusA1 to facilitate ribosome recycling may be altered, thereby changing the dynamics of translation. For example, if dissociation of ribosomes from key "stall sites" or stop signals becomes even slightly impaired, ribosomes will start to queue-up at such sites, affecting the translation of the protein encoded on the mRNA. If that protein was itself associated (either directly or indirectly) with aminoglycoside resistance, this would provide a tangible link between the mutation in fusA1 and the AMR phenotype.

This problem will be investigated using RNA-seq, Ribo-seq and ChIP-seq, and structural analyses, as well as the specialized proteomic approaches of TurboID and "OOPS" and biochemical assays. The project will also involve short-term travel to other laboratories and close collaboration with a network of researchers across Cambridge and beyond.

The University of Cambridge is a signatory to the San-Francisco Declaration on Research (Assessment DORA) and in recruitment or promotion evaluations will assess research on the basis of its merits rather than the journal or venue in which it is published. Applicants should not include Journal Impact Factors or uncontextualised metrics in their applications. For more information: https://www.research-strategy.admin.cam.ac.uk/research-policy/DORA

Fixed-term: The funds for this post are available from 01 March 2025 until 29 February 2028 in the first instance.

Click the 'Apply' button below to register an account with our recruitment system (if you have not already) and apply online.

Informal enquiries are welcomed and should be directed to Professor Martin Welch: mw240@cam.ac.uk.

For any questions about this vacancy or the application process please contact: personnel@bioc.cam.ac.uk.

Please quote reference PH43823 on your application and in any correspondence about this vacancy.

The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.

The University has a responsibility to ensure that all employees are eligible to live and work in the UK.

Apply now


Add to shortlist

Login or create a free user account to upload your CV and shortlist jobs.

Create account

Looking for something specific?